サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1468272

中枢神経系治療薬市場レポート：疾患・用途・地域別、2024年～2032年

Central Nervous System Therapeutics Market Report by Disease, Application, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 137 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
中枢神経系治療薬市場レポート：疾患・用途・地域別、2024年～2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 137 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の中枢神経系（CNS）治療薬市場規模は、2023年に1,401億米ドルに達しました。今後、IMARC Groupは、2032年には2,391億米ドルに達し、2024～2032年の成長率（CAGR）は5.9%になると予測しています。大衆の間で神経疾患や精神疾患の有病率が高まっていること、遠隔医療や遠隔医療サービスの増加、貿易協定やパートナーシップの増加が市場成長を促進する主な要因の一つです。

中枢神経系（CNS）治療薬は、中枢神経系を構成する脳と脊髄に影響を及ぼす障害の治療と管理に焦点を当てています。これらの疾患は、アルツハイマー病やパーキンソン病などの神経変性疾患から、うつ病や不安神経症などの精神疾患まで多岐にわたる。また、外傷性脳損傷や脳卒中などの急性疾患も含まれます。治療法は多岐にわたり、薬理学的介入、外科的処置、遺伝子治療などの新しい方法など、さまざまなアプローチがあります。薬物療法には、抗うつ薬、抗精神病薬、神経経路を標的とした薬剤などがあります。この分野の研究は、神経科学とバイオテクノロジーの進歩に牽引され、絶えず進化しています。

中枢神経系（CNS）治療薬業界の市場促進要因のひとつは、神経疾患や精神疾患の世界の有病率の上昇です。アルツハイマー病、パーキンソン病、うつ病、不安神経症などの疾患は、高齢化、ライフスタイルの変化、環境ストレスなどの要因により、ますます一般的になってきています。中枢神経系治療薬を必要とする患者の増加に伴い、市場の可能性は拡大し続けており、投資と技術革新にとって魅力的な分野となっています。これに伴い、遠隔医療や遠隔医療サービスの増加が市場成長の重要な促進要因となっています。COVID-19の流行は遠隔ヘルスケアの導入を加速させ、この動向は今後も続くと思われます。遠隔医療サービスを利用すれば、患者は実際に診察を受けることなく、医療アドバイスを求めたり、中枢神経系疾患の処方箋を入手したりすることができるため、利便性が向上します。このようなアクセス性の向上は、特に遠隔地の患者にとって有益であり、CNS治療薬の患者層を広げることになります。さらに、規制当局も革新的な中枢神経系治療薬、特にアンメットニーズに対応する薬剤の早期承認に前向きになっています。そのため、市場にも貢献しています。さらに、貿易協定やパートナーシップは世界化によって促進されることが多く、中枢神経系治療薬のより合理的な流通網を提供し、市場の前向きな見通しを生み出しています。

中枢神経系（CNS）治療薬市場の動向と促進要因：

創薬技術の進歩

技術の急速な進歩は、中枢神経系治療薬業界にとって極めて重要な推進力となっています。従来の創薬手法は、人工知能（AI）、機械学習、ビッグデータ解析などの技術によって拡張されつつあります。これらの技術は、潜在的な薬剤候補の迅速な特定に役立ち、それによって薬剤開発のプロセスを加速させています。ハイスループット・スクリーニング法もより洗練され、研究者は短期間で数千の化合物を評価できるようになった。バイオインフォマティクス・ツールや計算モデルは、分子レベルで疾患経路を理解するためにますます使用されるようになり、標的治療の開発に役立っています。このような技術の進歩により、中枢神経系の新薬の上市にかかる時間とコストが大幅に削減され、業界の成長に力強い原動力となっています。

国民の意識とヘルスケア・インフラ

メンタルヘルスや神経疾患に対する人々の意識は、近年著しく高まっています。こうした意識の高まりが早期診断・早期治療につながり、CNS治療薬の需要を牽引しています。さらに、政府や医療機関がメンタルヘルスの重要性を認識するようになり、CNS治療薬の開発・流通を促進するヘルスケア・インフラや政策の改善につながっています。多くの先進国では、神経疾患や精神疾患の治療にも保険が適用されるようになり、より多くの人々が治療を受けられるようになっています。神経科クリニックやリハビリテーション・センターなどの専門ヘルスケア施設の増加も、中枢神経系治療薬の市場ポテンシャルをさらに高めています。ヘルスケアのインフラが改善し続ければ、効果的で革新的な中枢神経系治療薬の市場も拡大します。

研究開発への投資拡大

研究開発（R&D）は中枢神経系治療薬産業の屋台骨を形成しており、この分野への投資の拡大は市場の大きな促進要因となっています。さらに、製薬企業は研究開発活動に多大なリソースを投入しており、学術機関や研究組織と連携することも多いです。このような提携により、専門知識や資金が共有され、開発プロセスが促進されます。さらに、政府からの助成金、ベンチャーキャピタルからの資金提供、官民パートナーシップも、研究開発活動を支援する役割をますます果たしています。このような協力的な環境は、中枢神経系疾患を治療するための標的治療薬や個別化医療のアプローチなど、画期的な発見につながっています。高い投資収益が期待できることに加え、効果的な治療法に対する需要が常に存在するため、研究開発資金はCNS治療薬産業の成長を強力に後押ししています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 中枢神経系（CNS）治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：疾患別

  • 神経変性疾患
    • 市場動向
    • 主要セグメント
      • アルツハイマー病
      • パーキンソン病
      • 多発性硬化症
      • ハンチントン病
      • 筋萎縮性側索硬化症
      • その他
    • 市場予測
  • 神経血管疾患
    • 市場動向
    • 市場予測
  • 中枢神経系外傷
    • 市場動向
    • 市場予測
  • メンタルヘルス
    • 市場動向
    • 主要セグメント
      • 不安障害
      • てんかん
      • 気分障害
      • 精神病性障害
      • その他
    • 市場予測
  • 感染症
    • 市場動向
    • 市場予測
  • 中枢神経系がん
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：用途別

  • 病院
    • 市場動向
    • 市場予測
  • クリニック
    • 市場動向
    • 市場予測
  • ホームケア
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第9章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第10章 バリューチェーン分析

第11章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第12章 価格分析

第13章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AstraZeneca plc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG（Roche Holding）
    • H. Lundbeck A/S
    • Merck & Co. Inc.
    • Neurocrine Biosciences Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Central Nervous System Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Central Nervous System Therapeutics Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Central Nervous System Therapeutics Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Central Nervous System Therapeutics Market: Breakup by Disease (in %), 2023
  • Figure 5: Global: Central Nervous System Therapeutics Market: Breakup by Application (in %), 2023
  • Figure 6: Global: Central Nervous System Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 7: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Central Nervous System Therapeutics (Neurodegenerative Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Central Nervous System Therapeutics (Neurovascular Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Central Nervous System Therapeutics (CNS Trauma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Central Nervous System Therapeutics (CNS Trauma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Central Nervous System Therapeutics (Mental Health) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Central Nervous System Therapeutics (Mental Health) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Central Nervous System Therapeutics (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Central Nervous System Therapeutics (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Central Nervous System Therapeutics (CNS Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Central Nervous System Therapeutics (CNS Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Central Nervous System Therapeutics (Other Diseases) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Central Nervous System Therapeutics (Other Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Central Nervous System Therapeutics (Hospital) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Central Nervous System Therapeutics (Hospital) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Central Nervous System Therapeutics (Clinic) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Central Nervous System Therapeutics (Clinic) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Central Nervous System Therapeutics (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Central Nervous System Therapeutics (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Central Nervous System Therapeutics (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Central Nervous System Therapeutics (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: North America: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: North America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: United States: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: United States: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Canada: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Canada: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Asia-Pacific: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Asia-Pacific: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: China: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: China: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Japan: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Japan: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: India: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: India: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: South Korea: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: South Korea: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Australia: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Australia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Indonesia: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Indonesia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Europe: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Europe: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Germany: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Germany: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: France: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: France: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: United Kingdom: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: United Kingdom: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Italy: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Italy: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Spain: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Spain: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Russia: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Russia: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Latin America: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Latin America: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Brazil: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Brazil: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Mexico: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Mexico: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Middle East and Africa: Central Nervous System Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Middle East and Africa: Central Nervous System Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 77: Middle East and Africa: Central Nervous System Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Global: Central Nervous System Therapeutics Industry: SWOT Analysis
  • Figure 79: Global: Central Nervous System Therapeutics Industry: Value Chain Analysis
  • Figure 80: Global: Central Nervous System Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Central Nervous System Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Disease (in Million US$), 2024-2032
  • Table 3: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 4: Global: Central Nervous System Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Central Nervous System Therapeutics Market: Competitive Structure
  • Table 6: Global: Central Nervous System Therapeutics Market: Key Players
目次
Product Code: SR112024A6114

The global central nervous system (CNS) therapeutics market size reached US$ 140.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 239.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032. The growing prevalence of neurological and psychiatric disorders among the masses, the rise in telehealth and telemedicine services, and the increase in trade agreements and partnerships are among the key factors driving the market growth.

Central nervous system (CNS) therapeutics focus on the treatment and management of disorders affecting the brain and spinal cord, which make up the central nervous system. These disorders can range from neurodegenerative diseases, such as Alzheimer's and Parkinson's to psychiatric conditions such as depression and anxiety. They also cover acute conditions, including traumatic brain injuries and strokes. The treatment landscape is vast and includes various approaches, such as pharmacological interventions, surgical procedures, and newer modalities, including gene therapy. Medications can consist of antidepressants, antipsychotics, or drugs specifically designed to target neural pathways. Research in this field is continually evolving, driven by advancements in neuroscience and biotechnology.

One of the primary market drivers for the central nervous system (CNS) therapeutics industry is the rising prevalence of neurological and psychiatric disorders globally. Conditions such as Alzheimer's, Parkinson's, depression, and anxiety are becoming increasingly common due to factors, such as an aging population, lifestyle changes, and environmental stressors. With an increasing number of patients requiring CNS therapeutics, the market potential continues to expand, making it an attractive area for investment and innovation. Along with this, the rise in telehealth and telemedicine services is proving to be a significant driver in the market growth. The COVID-19 pandemic has accelerated the adoption of remote healthcare, and this trend is likely to continue. Telehealth services make it more convenient for patients to seek medical advice and obtain prescriptions for CNS disorders without the need for physical appointments. This increased accessibility is particularly beneficial for those in remote areas, broadening the patient base for CNS therapeutics. In addition, regulatory agencies are showing an increased willingness to fast-track the approval of innovative CNS therapeutic drugs, particularly those addressing unmet medical needs. Therefore, it is contributing to the market. Moreover, trade agreements and partnerships are often facilitated by globalization, providing a more streamlined distribution network for CNS therapeutic products, and creating a positive market outlook.

Central Nervous System (CNS) Therapeutics Market Trends/Drivers:

Technological Advancements in Drug Discovery

The rapid advancements in technology have been a crucial driver for the CNS therapeutics industry. Traditional methods of drug discovery are being augmented by technologies such as artificial intelligence (AI), machine learning, and big data analytics. These technologies help in quicker identification of potential drug candidates, thereby speeding up the process of drug development. High-throughput screening methods have also become more sophisticated, allowing researchers to evaluate thousands of compounds in a shorter time frame. Bioinformatics tools and computational models are increasingly used for understanding disease pathways at the molecular level, aiding in the development of targeted therapies. These technological strides have significantly reduced the time and cost associated with bringing a new CNS therapeutic drug to market, providing a robust impetus for industry growth.

Public Awareness and Healthcare Infrastructure

Public awareness about mental health and neurological disorders has grown significantly in recent years. This increased awareness has led to early diagnosis and treatment, subsequently driving the demand for CNS therapeutics. Furthermore, governments and healthcare organizations are increasingly recognizing the importance of mental health, leading to better healthcare infrastructure and policies that facilitate the development and distribution of CNS drugs. In many developed countries, insurance coverage has expanded to include treatments for neurological and psychiatric disorders, making therapies more accessible to a broader population. The rise in specialized healthcare facilities, such as neurology clinics and rehabilitation centers, adds another layer of market potential for CNS therapeutics. As healthcare infrastructure continues to improve, so does the market for effective and innovative CNS treatments.

Growing Investment in Research and Development

Research and development (R&D) form the backbone of the CNS therapeutics industry, and growing investment in this area serves as a substantial market driver. Additionally, pharmaceutical companies are dedicating significant resources to R&D activities, often in collaboration with academic institutions and research organizations. Such partnerships facilitate the sharing of expertise and financial resources, thereby expediting the development process. In addition, government grants, venture capital funding, and public-private partnerships are also playing an increasing role in supporting R&D efforts. This collaborative environment has led to groundbreaking discoveries, including targeted therapies and personalized medicine approaches for treating CNS disorders. The promise of high returns on investment, coupled with the ever-present demand for effective treatments, ensures that R&D funding remains a strong driver for the growth of the CNS Therapeutics industry.

Central Nervous System (CNS) Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the central nervous system (CNS) therapeutics market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on disease and application.

Breakup by Disease:

Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Multiple Sclerosis

Huntington's Disease

Amyotrophic Lateral Sclerosis

Others

Neurovascular Diseases

CNS Trauma

Mental Health

Anxiety Disorders

Epilepsy

Mood Disorders

Psychotic Disorders

Others

Infectious Diseases

CNS Cancer

Others

Neurodegenerative Diseases represent the largest market share

The report has provided a detailed breakup and analysis of the market based on the disease. This includes neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, amyotrophic lateral sclerosis, and others), neurovascular diseases, CNS trauma, mental health (anxiety disorders, epilepsy, mood disorders, psychotic disorders, and others), infectious diseases, CNS cancer, and others. According to the report, neurodegenerative diseases accounted for the largest market share.

The rising incidence of neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Multiple Sclerosis is a significant market driver in the central nervous system (CNS) Therapeutics industry. As the global population ages, the prevalence of these conditions is expected to escalate, increasing the demand for effective treatments. Along with this, the socioeconomic burden these diseases place on healthcare systems and families is pushing both public and private sectors to invest heavily in research and development. Technological advancements, such as biomarker identification and gene editing, are accelerating the pace of drug discovery for neurodegenerative conditions, attracting further investment. Additionally, government initiatives and regulatory support, mainly fast-track approvals and grants, provide an impetus for pharmaceutical companies to develop innovative solutions. In addition, the growing public awareness and educational campaigns around neurodegenerative diseases are also contributing to market growth by encouraging early diagnosis and treatment. All these factors collectively create a conducive environment for the expansion of the CNS Therapeutics market in the domain of neurodegenerative diseases.

Breakup by Application:

Hospital

Clinic

Homecare

Others

A detailed breakup and analysis of the market based on the application has also been provided in the report. This includes hospital, clinic, homecare, and others.

The role of hospitals as a primary point of care for acute and chronic neurological conditions is a significant market driver in the central nervous system (CNS) therapeutics industry. Hospitals are often equipped with advanced diagnostic tools and treatment facilities, making them essential for managing complex CNS disorders. As cases of traumatic brain injuries, strokes, and emergency psychiatric episodes continue to rise, the need for specialized CNS therapeutics within hospital settings becomes increasingly crucial. The demand is further fueled by the growing number of specialized neurology departments and centers of excellence in hospitals, which require a consistent supply of CNS medications and treatments. Additionally, hospitals are key sites for clinical trials, accelerating the adoption of innovative CNS therapies.

On the contrary, the rising trend towards homecare for managing chronic and post-acute conditions is significantly influencing the Central Nervous System (CNS) therapeutics industry. As technological advancements make remote monitoring and telehealth more viable, many patients prefer receiving care in the comfort of their homes. Homecare is especially relevant for the elderly population and patients with neurodegenerative disorders who may find frequent hospital visits cumbersome. In addition, the availability of easy-to-administer medications and therapies suitable for home use is driving demand in this segment. Moreover, healthcare models are shifting towards more patient-centric approaches, further encouraging the adoption of homecare solutions. These trends not only broaden the consumer base but also open new channels for the distribution of CNS therapeutics, boosting overall market growth.

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest central nervous system (CNS) therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America exhibited the largest market segment.

The central nervous system (CNS) therapeutics industry in North America is driven by the high prevalence of CNS-related disorders, including mental health conditions, neurodegenerative diseases, and acute neurological issues. According to the Centers for Disease Control and Prevention (CDC), one in five American adults experiences mental illness each year. Furthermore, an aging population in the region significantly contributes to the increased incidence of age-related neurodegenerative diseases such as Alzheimer's and Parkinson's.

In addition, technological innovation is another significant driver, with North America often leading in the development of advanced treatments, including gene therapies and neural implants. The region also benefits from strong regulatory support, with agencies providing fast-track approvals for innovative CNS drugs. Moreover, robust healthcare infrastructure, including advanced hospitals and a growing focus on telehealth services, facilitates easier access to treatments. Furthermore, substantial investment in research and development, both from public and private sectors, furthers innovation and the speed-to-market for new CNS therapies, collectively making North America a dynamic market for CNS therapeutics.

Competitive Landscape:

The key players are allocating significant resources to advance their understanding of CNS disorders, uncover novel treatment approaches, and develop new therapeutic agents. This involves conducting clinical trials, and preclinical studies, and leveraging cutting-edge technologies to identify potential drug candidates. Along with this, brands are leveraging advanced techniques, such as high-throughput screening, molecular modeling, and genetics to discover compounds with the potential to modulate CNS-related targets. These efforts aim to identify effective drug candidates that can address specific neurological conditions. In addition, the growing focus on personalized medicine within the CNS therapeutics field is positively influencing the market. Apart from this, companies are particularly focused on neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Research efforts are aimed at unraveling the underlying mechanisms of these diseases and developing disease-modifying treatments, which act as another growth-inducing factor. Furthermore, the escalating number of collaborations with research institutions, academia, and other industry players to develop new therapeutic approaches is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc

Biogen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG (Roche Holding)

H. Lundbeck A/S

Merck & Co. Inc.

Neurocrine Biosciences Inc.

Novartis AG

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

Recent Developments:

In May 2023, AstraZeneca plc gained authorization from the Japanese Ministry of Health, Labour, and Welfare (MHLW) to use Ultomiris (ravulizumab) to stop relapses in patients with neuromyelitis optica spectrum disease (NMOSD), including neuromyelitis optica.

In January 2023, Biogen Inc. and Alcyone Therapeutics (Alcyone) engaged in a licence and cooperation agreement to create the ThecaFlex DRxTM System from Alcyone, an implanted medical device designed for subcutaneous antisense oligonucleotide (ASO) therapy administration into the intrathecal space.

In January 2023, Capsida Biotherapeutics Inc. established a multi-year strategic partnership to develop game-changing genetic treatments for critical illnesses with Prevail Therapeutics ("Prevail"), a fully owned subsidiary of Eli Lilly and Company ("Lilly").

Key Questions Answered in This Report

  • 1. What was the size of the global Central Nervous System (CNS) therapeutics market in 2023?
  • 2. What is the expected growth rate of the global Central Nervous System (CNS) therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global Central Nervous System (CNS) therapeutics market?
  • 4. What has been the impact of COVID-19 on the global Central Nervous System (CNS) therapeutics market?
  • 5. What is the breakup of the global Central Nervous System (CNS) therapeutics market based on the disease?
  • 6. What are the key regions in the global Central Nervous System (CNS) therapeutics market?
  • 7. Who are the key players/companies in the global Central Nervous System (CNS) therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Central Nervous System (CNS) Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Disease

  • 6.1 Neurodegenerative Diseases
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alzheimer's Disease
      • 6.1.2.2 Parkinson's Disease
      • 6.1.2.3 Multiple Sclerosis
      • 6.1.2.4 Huntington's Disease
      • 6.1.2.5 Amyotrophic Lateral Sclerosis
      • 6.1.2.6 Others
    • 6.1.3 Market Forecast
  • 6.2 Neurovascular Diseases
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 CNS Trauma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Mental Health
    • 6.4.1 Market Trends
    • 6.4.2 Key Segments
      • 6.4.2.1 Anxiety Disorders
      • 6.4.2.2 Epilepsy
      • 6.4.2.3 Mood Disorders
      • 6.4.2.4 Psychotic Disorders
      • 6.4.2.5 Others
    • 6.4.3 Market Forecast
  • 6.5 Infectious Diseases
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 CNS Cancer
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Hospital
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinic
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Homecare
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 AstraZeneca plc
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Biogen Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Eli Lilly and Company
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 F. Hoffmann-La Roche AG (Roche Holding)
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 SWOT Analysis
    • 13.3.5 H. Lundbeck A/S
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Merck & Co. Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Neurocrine Biosciences Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Pfizer Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Sanofi S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Takeda Pharmaceutical Company Limited
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis
    • 13.3.12 Teva Pharmaceutical Industries Ltd.
      • 13.3.12.1 Company Overview
      • 13.3.12.2 Product Portfolio
      • 13.3.12.3 Financials
      • 13.3.12.4 SWOT Analysis